Elicio Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $79.9M
- Price
- $3.04
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.14%
- Volume
- 279.4K
About
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Quick stats
Shares outstanding26.3M
Computed float7.3M
Float / shares28.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001601485
Websitehttps://elicio.com
AI Summary
AI-generated1/27
majorbearishearnings
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Elicio Therapeutics reported that its Phase 2 AMPLIFY-7P trial did not meet its primary endpoint in adjuvant pancreatic cancer, though the company continues to evaluate subgroups to refine its Phase 3 strategy.
Despite the setback, the company plans to initiate a Phase 1 combination study in metastatic pancreatic cancer in Q4 2026, citing encouraging complete response data from prior treatments.
Financially, Q2 net loss narrowed to $8.2 million ($0.43 per share) with cash balance at $23.5 million; recent financings totaling roughly $31.6 million extend runway only into Q1 2027.
Red flags
- Phase 2 AMPLIFY-7P trial did not meet its primary endpoint
- Cash runway extends only into Q1 2027, requiring additional funding soon